|
1
|
Knowles MA and Hurst CD: Molecular biology
of bladder cancer: New insights into pathogenesis and clinical
diversity. Nat Rev Cancer. 15:25–41. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Polo A, Crispo A, Cerino P, Falzone L,
Candido S, Giudice A, De Petro G, Ciliberto G, Montella M, Budillon
A and Costantini S: Environment and bladder cancer: Molecular
analysis by interaction networks. Oncotarget. 8:65240–65252. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cumberbatch MGK and Noon AP: Epidemiology,
aetiology and screening of bladder cancer. Transl Androl Urol.
8:5–11. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Alfred Witjes J, Lebret T, Compérat EM,
Cowan NC, De Santis M, Bruins HM, Hernández V, Espinós EL, Dunn J,
Rouanne M, et al: Updated 2016 EAU guidelines on muscle-invasive
and metastatic bladder cancer. Eur Urol. 71:462–475. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Falzone L, Salomone S and Libra M:
Evolution of cancer pharmacological treatments at the turn of the
third millennium. Front Pharmacol. 9:13002018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim R: Effects of surgery and anesthetic
choice on immunosuppression and cancer recurrence. J Transl Med.
16:82018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zheng X, Wang Y, Dong L, Zhao S, Wang L,
Chen H, Xu Y and Wang G: Effects of propofol-based total
intravenous anesthesia on gastric cancer: A retrospective study.
Onco Targets Ther. 11:1141–1148. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wigmore TJ, Mohammed K and Jhanji S:
Long-term survival for patients undergoing volatile versus IV
anesthesia for cancer surgery. Anesthesiology. 124:69–79. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Du Q, Liu J, Zhang X, Zhang X, Zhu H, Wei
M and Wang S: Propofol inhibits proliferation, migration, and
invasion but promotes apoptosis by regulation of Sox4 in
endometrial cancer cells. Br J Med Biol Res. 51:e68032018.
View Article : Google Scholar
|
|
10
|
Zhang J, Zhang D, Wu GQ, Feng ZY and Zhu
SM: Propofol inhibits the adhesion of hepatocellular carcinoma
cells by upregulating microRNA-199a and downregulating MMP-9
expression. Hepatobiliary Pancreat Dis Int. 12:305–309. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang L, Wang N, Zhou S, Ye W, Jing G and
Zhang M: Propofol induces proliferation and invasion of gallbladder
cancer cells through activation of Nrf2. J Exp Clin Cancer Res.
31:662012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li Q, Wang H, Peng H, Huang Q, Huyan T,
Huang Q, Yang H and Shi J: MicroRNAs: Key players in bladder
cancer. Mol Diagn Ther. 23:579–601. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dyrskjøt L, Ostenfeld MS, Bramsen JB,
Silahtaroglu AN, Lamy P, Ramanathan R, Fristrup N, Jensen JL,
Andersen CL, Zieger K, et al: Genomic profiling of microRNAs in
bladder cancer: MiR-129 is associated with poor outcome and
promotes cell death in vitro. Cancer Res. 69:4851–4860. 2009.
View Article : Google Scholar
|
|
14
|
Dip N, Reis ST, Srougi M, Dall'Oglio MF
and Leite KR: Expression profile of microrna-145 in urothelial
bladder cancer. Int Braz J Urol. 39:95–102. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pignot G, Cizeron-Clairac G, Vacher S,
Susini A, Tozlu S, Vieillefond A, Zerbib M, Lidereau R, Debre B,
Amsellem-Ouazana D and Bieche I: microRNA expression profile in a
large series of bladder tumors: Identification of a 3-miRNA
signature associated with aggressiveness of muscle-invasive bladder
cancer. Int J Cancer. 132:2479–2491. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Minami K, Taniguchi K, Sugito N, Kuranaga
Y, Inamoto T, Takahara K, Takai T, Yoshikawa Y, Kiyama S, Akao Y
and Azuma H: MiR-145 negatively regulates Warburg effect by
silencing KLF4 and PTBP1 in bladder cancer cells. Oncotarget.
8:33064–33077. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Blick C, Ramachandran A, McCormick R,
Wigfield S, Cranston D, Catto J and Harris AL: Identification of a
hypoxia-regulated miRNA signature in bladder cancer and a role for
miR-145 in hypoxia-dependent apoptosis. Br J Cancer. 113:634–644.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chiyomaru T, Enokida H, Tatarano S,
Kawahara K, Uchida Y, Nishiyama K, Fujimura L, Kikkawa N, Seki N
and Nakagawa M: miR-145 and miR-133a function as tumour suppressors
and directly regulate FSCN1 expression in bladder cancer. Br J
Cancer. 102:883–891. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu KZ, Wang GN, Fitzgerald J, Quachthithu
H, Rainey MD, Cattaneo A, Bachi A and Santocanale C: DDK dependent
regulation of TOP2A at centromeres revealed by a chemical genetics
approach. Nucleic Acids Res. 44:8786–8798. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang R, Xu J, Zhao J and Bai JH:
Proliferation and invasion of colon cancer cells are suppressed by
knockdown of TOP2A. J Cell Biochem. 119:7256–7263. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pei YF, Yin XM and Liu XQ: TOP2A induces
malignant character of pancreatic cancer through activating
β-catenin signaling pathway. Biochim Biophys Acta Mol Basis Dis.
1864:197–207. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Slamon DJ and Press MF: Alterations in the
TOP2A and HER2 genes: Association with adjuvant anthracycline
sensitivity in human breast cancers. J Natl Cancer Inst.
101:615–618. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Micael Reis CPV, Morales-Hojas R, Aguiar
B, Rocha H, Schlötterer C and Vieira J: Fold change in regucalcin
expression after chill-coma recovery (ChCR) obtained by qRT-PCR
using the 2-∆∆Ct method. PLoS One. 6:e255202011.PubMed/NCBI
|
|
24
|
Cao R, Meng Z, Liu T, Wang G, Qian G, Cao
T, Guan X, Dan H, Xiao Y and Wang X: Decreased TRPM7 inhibits
activities and induces apoptosis of bladder cancer cells via ERK1/2
pathway. Oncotarget. 7:72941–72960. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Garib V, Lang K, Niggemann B, Zänker KS,
Brandt L and Dittmar T: Propofol-induced calcium signalling and
actin reorganization within breast carcinoma cells. Eur J
Anaesthesiol. 22:609–615. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Miao Y, Zhang Y, Wan H, Chen L and Wang F:
GABA-receptor agonist, propofol inhibits invasion of colon
carcinoma cells. Biomed Pharmacother. 64:583–588. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Qi Z, Yuan L and Sun N: Propofol exhibits
a tumor-suppressive effect and regulates cell viability, migration
and invasion in bladder carcinoma by targeting the
microRNA-10b/HOXD10 signaling pathway. Oncol Let. 18:6228–6236.
2019.
|
|
28
|
Zhang W, Wang Y, Zhu Z, Zheng Y and Song
B: Propofol inhibits proliferation, migration and invasion of
gastric cancer cells by up-regulating microRNA-195. Int J Biol
Macromol. 120:975–984. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu WZ and Liu N: Propofol inhibits lung
cancer A549 cell growth and epithelial-mesenchymal transition
process by upregulation of MicroRNA-1284. Oncol Res. 27:1–8. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sun H and Gao D: Propofol suppresses
growth, migration and invasion of A549 cells by down-regulation of
miR-372. BMC Cancer. 18:12522018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Guerrero Orriach JL, Raigon Ponferrada A,
Malo Manso A, Herrera Imbroda B, Escalona Belmonte JJ, Ramirez
Aliaga M, Ramirez Fernandez A, Diaz Crespo J, Soriano Perez AM,
Fontaneda Heredia A, et al: Anesthesia in combination with propofol
increases disease-free survival in bladder cancer patients who
undergo radical tumor cystectomy as compared to inhalational
anesthetics and opiate-based analgesia. Oncology. 98:161–167. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hang W, Feng Y, Sang Z, Yang Y, Zhu Y,
Huang Q and Xi X: Downregulation of miR-145-5p in cancer cells and
their derived exosomes may contribute to the development of ovarian
cancer by targeting CT. Int J Mol Med. 43:256–266. 2019.PubMed/NCBI
|
|
33
|
Thuringer D, Jego G, Berthenet K, Hammann
A, Solary E and Garrido C: Gap junction-mediated transfer of
miR-145-5p from microvascular endothelial cells to colon cancer
cells inhibits angiogenesis. Oncotarget. 7:28160–28168. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xue D, Lu H, Xu HY, Zhou CX and He XZ:
Long noncoding RNA MALAT1 enhances the docetaxel resistance of
prostate cancer cells via miR-145-5p-mediated regulation of AKAP12.
J Cell Mol Med. 22:3223–3237. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang H, Jiang M, Liu Q, Han Z, Zhao Y and
Ji S: miR-145-5p inhibits the proliferation and migration of
bladder cancer cells by targeting TAGLN2. Oncol Lett. 16:6355–6360.
2018.PubMed/NCBI
|
|
36
|
Zhu Z, Xu T, Wang L, Wang X, Zhong S, Xu C
and Shen Z: MicroRNA-145 directly targets the insulin-like growth
factor receptor I in human bladder cancer cells. FEBS Lett.
588:3180–3185. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fujii T, Shimada K, Tatsumi Y, Hatakeyama
K, Obayashi C, Fujimoto K and Konishi N: microRNA-145 promotes
differentiation in human urothelial carcinoma through
down-regulation of syndecan-1. BMC Cancer. 15:8182015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Deng S, Yan T, Nikolova T, Fuhrmann D,
Nemecek A, Gödtel-Armbrust U, Kaina B and Wojnowski L: The
catalytic topoisomerase II inhibitor dexrazoxane induces DNA
breaks, ATF3 and the DNA damage response in cancer cells. Br J
Pharmacol. 172:2246–2257. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen T, Sun Y, Ji P, Kopetz S and Zhang W:
Topoisomerase IIα in chromosome instability and personalized cancer
therapy. Oncogene. 34:4019–4031. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang Y, Zhao Y, Herbst A, Kalinski T, Qin
J, Wang X, Jiang Z, Benedix F, Franke S, Wartman T, et al: miR-221
mediates chemoresistance of esophageal adenocarcinoma by direct
targeting of DKK2 expression. Ann Surg. 264:804–814. 2016.
View Article : Google Scholar : PubMed/NCBI
|
